Overview

Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled Tozadenant

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate how tozadenant is absorbed, distributed, broken down and eliminated from the body. The compound to be administered will be radiolabeled. This enables the investigator to trace the compound in blood, urine, feces, expired air and track what happens to it.
Phase:
Phase 1
Details
Lead Sponsor:
Biotie Therapies Inc.
Collaborators:
PRA Health Sciences
Tandem Labs
Xceleron Inc